Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingCarolina Behavioral Genetic Testing Coverage | Ope…
    Ask Trek AI about this page
    ModifiedCarolina Behavioral Health AlliancePolicy N/A

    Concert Genetic Testing: General Approach to Genetic and Molecular Testing

    Customize your policy alerts

    Sign up for all carolinabehavioralhealth policy alerts

    Know when carolinabehavioralhealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy establishes general medical-necessity criteria for genetic and molecular tests not specifically addressed by another policy or section, including familial variant analysis, carrier screening, single- or multigene testing, prenatal single-gene diagnosis, tumor biomarker analysis, oncology algorithmic testing, and other genetic tests.

    Policy Summary
    PayerCarolina Behavioral Health Alliance
    PolicyConcert Genetic Testing: General Approach to Genetic and Molecular Testing
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the indication and applicable clinical criteria, including relevant phenotype or diagnosis, family or reproductive history, prior clinical evaluation and standard testing, clinical validity and utility, relevant familial variant information, and the intended effect on treatment, management, prognosis, or disease-risk assessment.
    SourceLink
    POLICY UPDATE CHANGES

    The targeted prenatal screening definition was revised to include full-gene sequencing or targeted mutation analysis for a pathogenic or likely pathogenic variant in a gene associated with a specific genetic condition.

    Age restriction criteria were removed for adult-onset testing under the single-gene or multigene panel criteria.

    Prenatal Diagnosis for Genetic Conditions was added to this policy.

    Coverage criteria for oncology algorithmic tests, single-gene or multigene panel analysis, tumor biomarker analysis, and other tests were updated to assess clinical validity and clinical utility.

    7

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    General genetic testing criteria categories addressed
    CLIALaboratory standard for tumor biomarker and other tests
    18 yearsAdult-onset threshold for known familial variant analysis
    4Clinical-utility pathways supporting coverage
    11/2024Last revision

    Medical Necessity Criteria

    Known Familial Variant Analysis

    Targeted mutation analysis for a known familial pathogenic or likely pathogenic variant may be considered medically necessary when ALL of the following are met:

    ALL of the following

    • The member/enrollee is 18 years or older when the condition is adult-onset.
    • A close relative has a known pathogenic or likely pathogenic variant causing the condition.
    • An association between the gene and disease has been established.

    Targeted Carrier Screening

    Targeted carrier screening, defined as full-gene sequencing or targeted mutation analysis for a pathogenic or likely pathogenic variant in a gene associated with a specific genetic condition, may be considered medically necessary when ALL of the following are met:

    ALL of the following

    • The member/enrollee is considering pregnancy or is currently pregnant.
    • The genetic disorder is a recessive condition with childhood onset.
    • ONE of the following

      • The member/enrollee has a close relative with a known pathogenic or likely pathogenic variant associated with the disorder.
      • The member/enrollee's reproductive partner is a carrier for the genetic disorder.
      • The member/enrollee or the member's reproductive partner belongs to a population known to have a carrier rate of 1% or higher for the genetic condition.
      • The member/enrollee or the member/enrollee's reproductive partner has a first- or second-degree relative affected with the genetic disorder.

    Single-Gene or Multigene Panel Analysis

    Single-gene or multigene panel analysis may be considered medically necessary when ALL of the following are met:

    ALL of the following

    • The member/enrollee displays clinical features of the suspected genetic condition.
    • The diagnosis remains uncertain after appropriate clinical evaluation and other standard laboratory tests, imaging, and other relevant evaluation have been performed.
    • The test has clinical validity, demonstrated by accurately determining diagnostic, prognostic, or clinical information for a disease.
    • At least ONE clinical-utility criterion

      • The test will determine whether a particular therapeutic intervention is effective or ineffective, or whether an intervention may be harmful to the member/enrollee.

    Prenatal Diagnosis for Single-Gene Disorders

    Prenatal diagnosis for a single-gene disorder by amniocentesis, chorionic villus sampling (CVS), or percutaneous umbilical blood sampling (PUBS) may be considered medically necessary when ALL of the following are met:

    ALL of the following

    • At least ONE parental or reproductive-risk criterion

      • At least one biological parent has a known pathogenic variant for an autosomal dominant condition.
      • Both biological parents are known carriers of an autosomal recessive condition.
      • One biological parent is suspected or known to be a carrier of an X-linked condition.
      • The member/enrollee has a history of a previous child with a genetic condition and is suspected to have germline mosaicism.

    Tumor Biomarker Analysis

    General tumor biomarker analysis may be considered medically necessary when ALL of the following are met:

    ALL of the following

    • The member/enrollee has a confirmed neoplasm and/or malignancy.
    • The test has clinical validity, demonstrated by accurately determining diagnostic, prognostic, or clinical information for a disease.
    • At least ONE clinical-utility criterion

      • The test will determine whether a particular therapeutic intervention is effective or ineffective, or whether an intervention may be harmful to the member/enrollee.
      • The test will directly impact the member/enrollee's clinical management.

    Oncology Algorithmic Testing

    Oncology algorithmic testing may be considered medically necessary when ALL of the following are met:

    ALL of the following

    • The member/enrollee has a suspected or confirmed neoplasm and/or malignancy.
    • The test has clinical validity, demonstrated by accurately determining diagnostic, prognostic, or clinical information for a disease.
    • At least ONE clinical-utility criterion

      • The test will determine whether a particular therapeutic intervention is effective or ineffective, or whether an intervention may be harmful to the member/enrollee.
      • The test will directly impact the member/enrollee's clinical management.

    Other Genetic and Molecular Tests

    Other genetic and molecular tests may be considered medically necessary when ALL of the following are met:

    ALL of the following

    • The member/enrollee displays relevant clinical features consistent with the intended use of the test.
    • The test has clinical validity, demonstrated by accurately determining diagnostic, prognostic, or clinical information for a disease.
    • At least ONE clinical-utility criterion

      • The test will determine whether a particular therapeutic intervention is effective or ineffective, or whether an intervention may be harmful to the member/enrollee.
      • The test will directly impact the member/enrollee's clinical management.

    Prenatal diagnosis for adult-onset single-gene disorders, including testing by amniocentesis, CVS, or PUBS, is not medically necessary when the condition is not expected to affect pregnancy or childhood management.

    Because expanded carrier-screening panels may include many conditions, selected disorders should generally have a carrier frequency of at least 1 in 100, a well-defined phenotype, detrimental effects on quality of life, cognitive or physical impairment, a need for surgical or medical intervention, or onset early in life. Conditions should be diagnosable prenatally and may offer opportunities for antenatal intervention, delivery-management changes, or parental education about special care needs after birth.

    Testing should optimally be deferred until the individual can weigh the risks, benefits, and limitations of the information, taking the individual's circumstances, preferences, and beliefs into account and preserving the individual's autonomy and right to an open future. Decisions about genetic testing and screening should be driven by the best interests of the child.

    Carrier testing in minors should be limited to circumstances in which the result has medical relevance during childhood or is otherwise in the child's best interest.

    Prenatal diagnosis for adult-onset single-gene disorders by amniocentesis, CVS, or PUBS is considered not medically necessary in these circumstances. Prenatal diagnosis is also investigational for variants of unknown significance and for all other indications not meeting the medical-necessity criteria.

    Documentation Required

    Clinical and Genetic Documentation

    Document the clinical and genetic rationale supporting the requested test before ordering and submitting the request.

    • Document the relevant phenotype and clinical features, suspected or established diagnosis, and results of appropriate clinical evaluation, standard laboratory testing, imaging, and evaluation of non-genetic causes.
    • Document the personal, family, reproductive, and pregnancy history supporting the indication, including affected relatives, known familial pathogenic or likely pathogenic variants, parental carrier status, prior child with a genetic condition, suspected germline mosaicism, and relevant parental or population risk.
    • Document prior genetic testing and its results, including any known familial variant, variant classification, prior testing limitations, and why the requested test is more appropriate than targeted variant analysis or another available test.
    • Document the test's clinical validity, expected clinical utility, intended impact on treatment or management, and the laboratory's CLIA approval when required.
    • Document that pretest counseling was provided, including the purpose and scope of testing, potential results and limitations, residual risk, possible implications for the member/enrollee and family, available interventions, privacy or discrimination considerations when relevant, and informed consent or the member's decision to decline testing.

    Clinical Utility and Covered Situations

    Familial Variant Testing

    Targeted mutation analysis for a known familial pathogenic or likely pathogenic variant may be medically necessary when ALL of the following apply:

    Familial variant testing

    • Applicable age: The member/enrollee is 18 years or older if the condition is adult-onset.18 years or older for adult-onset conditions
    • Close-relative variant: A close relative has a known pathogenic or likely pathogenic variant causing the condition.
    • Established association: An association between the gene and disease has been established.

    Eligibility Requirements

    For known familial variant analysis, eligibility requires a close relative with a known pathogenic or likely pathogenic variant causing the condition. Close relatives include first-, second-, and third-degree blood relatives on the same side of the family. For targeted carrier screening, eligibility requires pregnancy or pregnancy planning, a childhood-onset recessive disorder, and at least one qualifying risk factor: a close relative with a known pathogenic or likely pathogenic variant, a reproductive partner who is a carrier, a population carrier rate of 1% or higher, or an affected first- or second-degree relative.

    For single-gene or multigene panel analysis, the diagnosis must remain uncertain after appropriate clinical evaluation and other standard laboratory tests, imaging, or similar testing. The member must have relevant clinical features, and non-genetic causes must be ruled out. The test must have established clinical validity and clinical utility, with at least one expected use involving treatment response or potential harm, direct clinical-management impact, prognosis, or refinement of natural history, recurrence risk, or predicted disease course. A more appropriate targeted familial-variant test must not be available, and the gene or panel must have an established disease association.

    Documentation and Ordering Guidance

    Documentation Required

    Confirm laboratory qualification

    When required for the applicable test category, document that testing is performed in a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory. This requirement applies to general tumor biomarker analysis and other genetic or molecular tests.

    Documentation Required

    Evaluate the multigene panel before ordering

    Before ordering a multigene panel, evaluate and document the test’s analytic validity, clinical validity, and clinical utility, along with the patient’s clinical and family history. Also document the panel’s gene content, sequencing and informatics limitations, and variant interpretation and reporting practices.

    Documentation Required

    Document pretest counseling

    Document pretest counseling before genetic testing, including potential result types, sensitivity, specificity, risks, limitations, benefits, positive and negative predictive values, residual risk where applicable, and the possible need for follow-up diagnostic testing. Patients must have the option to decline testing.

    Investigational and Noncovered Uses

    Also investigational are tumor biomarker analysis, oncology algorithmic testing, and other genetic or molecular tests that do not meet the applicable clinical-condition, clinical-validity, clinical-utility, or laboratory requirements. Predictive testing of minors for adult-onset conditions is not supported when results will not affect childhood medical management or significantly benefit the child, and routine carrier testing of minors for recessive conditions is not supported when carrier status has no medical relevance during minority. Prenatal testing for known adult-onset conditions is not recommended when pregnancy or childhood management will not be affected.

    Genetic and Molecular Testing Background

    Genetic testing evaluates genomic, transcriptional, proteomic, or epigenetic variation for disease prevention, diagnosis, and treatment. Germline variants arise in egg or sperm cells and may be inherited, while somatic variants occur in individual cells or groups of cells and are not passed to offspring. Genetic conditions may result from a single pathogenic variant or from interactions among multiple genes and environmental factors. Molecular testing may also evaluate tumor biomarkers or combine biomarkers with clinical data to generate diagnostic, prognostic, or treatment recommendations.

    Policy Definitions

    Adult-onset condition
    DefinitionA condition in which signs, symptoms, or manifestations typically begin after a person is 18 years or older.
    Age threshold18 years or older.
    Policy relevanceAdult-onset status is used when applying age-related genetic-testing criteria.
    Childhood
    DefinitionThe period of development until the 18th birthday.
    End of childhoodThe 18th birthday.
    Policy relevanceChildhood onset is relevant to targeted carrier-screening criteria.
    Policy Summary
    PayerCarolina Behavioral Health Alliance
    PolicyConcert Genetic Testing: General Approach to Genetic and Molecular Testing
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the indication and applicable clinical criteria, including relevant phenotype or diagnosis, family or reproductive history, prior clinical evaluation and standard testing, clinical validity and utility, relevant familial variant information, and the intended effect on treatment, management, prognosis, or disease-risk assessment.
    SourceLink
    On This Page
    Medical Necessity CriteriaClinical Utility and Covered SituationsEligibility RequirementsDocumentation and Ordering GuidanceInvestigational and Noncovered UsesGenetic and Molecular Testing BackgroundPolicy Definitions
    The test will directly impact the member/enrollee's clinical management.
  1. The test will determine prognosis.
  2. The test will provide or refine estimates of the natural history, recurrence risk, or predicted course of the genetic condition.
  3. There is no known pathogenic or likely pathogenic familial variant for which targeted variant analysis would be more appropriate.
  4. Non-genetic causes of the member/enrollee's clinical features, including pathogens, drug toxicity, and environmental factors, have been ruled out.
  5. An association between the gene or multigene panel and the disease has been established.
  6. The natural history of the disease is well understood, and there is a high likelihood that the disease has high morbidity.
  7. The genetic test has adequate sensitivity and specificity to guide clinical decision-making, and residual risk is understood.
  8. The test will determine prognosis.
  9. The test will provide or refine estimates of the natural history, recurrence risk, or predicted course of the genetic condition.
  10. Testing is performed in a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory.
  11. The test will determine prognosis.
  12. The test will provide or refine estimates of the natural history, recurrence risk, or predicted course of the genetic condition.
  13. The test will determine prognosis.
  14. The test will provide or refine estimates of the natural history, recurrence risk, or predicted course of the disease or genetic condition.
  15. Testing is performed in a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory.
  16. Targeted Carrier Screening

    Targeted carrier screening may be medically necessary when ALL baseline criteria and at least ONE qualifying risk factor are present:

    Targeted carrier-screening criteria

    • Pregnancy or pregnancy planning: The member/enrollee is considering pregnancy or is currently pregnant.
    • Childhood-onset recessive disorder: The genetic disorder is a recessive condition with a childhood onset.Childhood onset
    • ONE qualifying risk factor

      • Familial variant: The member/enrollee has a close relative with a known pathogenic or likely pathogenic variant associated with the disorder.
      • Partner carrier: The member/enrollee's reproductive partner is a carrier for the genetic disorder.
      • Population frequency: The member/enrollee or reproductive partner is a member of a population known to have a carrier rate of 1% or higher for the genetic condition.1% or higher
      • Affected relative: The member/enrollee or reproductive partner has a first- or second-degree relative affected with the genetic disorder.First- or second-degree relative

    Single-Gene or Multigene Panel Analysis

    Single-gene or multigene panel analysis for a suspected genetic condition may be medically necessary when ALL of the following are met, including at least ONE clinical-utility criterion:

    Required medical-necessity criteria

    • Clinical features: The member/enrollee displays clinical features of the suspected genetic condition.
    • Unresolved diagnosis: The diagnosis remains uncertain after appropriate clinical evaluation and other standard laboratory tests, imaging, or similar testing.
    • Clinical validity: The test has clinical validity.
    • ONE clinical-utility criterion

      • Therapeutic response or harm: The test will determine whether a therapeutic intervention is effective or ineffective, or whether an intervention may be harmful.
      • Clinical management: The test will directly impact clinical management.
      • Prognosis: The test will determine prognosis.
      • Natural history or recurrence risk: The test will provide or refine estimates of natural history, recurrence risk, or the predicted course of the genetic condition.
    • Targeted testing not more appropriate: There is no known pathogenic or likely pathogenic familial variant for which targeted variant analysis would be more appropriate.
    • Non-genetic causes excluded: Non-genetic causes of the clinical features, such as pathogens, drug toxicity, or environmental factors, have been ruled out.
    • Established gene-disease association: An association between the gene or multigene panel and disease has been established.

    Prenatal Diagnosis for Single-Gene Disorders

    Prenatal diagnosis of a single-gene disorder via amniocentesis, CVS, or PUBS may be medically necessary when ALL of the following are met:

    Prenatal diagnosis criteria

    • ONE qualifying genetic-risk circumstance

      • Autosomal dominant risk: At least one biological parent has a known pathogenic variant for an autosomal dominant condition.
      • Autosomal recessive risk: Both biological parents are known carriers of an autosomal recessive condition.
      • X-linked risk: One biological parent is suspected or known to be a carrier of an X-linked condition.
      • Germline mosaicism risk: The member/enrollee has a history of a previous child with a genetic condition and is suspected to have germline mosaicism.
    • Well-understood high-morbidity disease: The natural history of the disease is well-understood, and there is a high likelihood that the disease has high morbidity.
    • Adequate test performance: The genetic test has adequate sensitivity and specificity to guide clinical decision making, and residual risk is understood.

    General Tumor Biomarker Analysis

    General tumor biomarker analysis may be medically necessary when ALL of the following are met:

    General tumor biomarker criteria

    • Confirmed neoplasm or malignancy: The member/enrollee has a confirmed neoplasm and/or malignancy.
    • Clinical validity: The test has clinical validity.
    • ONE clinical-utility pathway

      • Therapeutic response or harm: The test will determine whether a therapeutic intervention is effective or ineffective, or whether an intervention may be harmful.
      • Clinical management: The test will directly impact clinical management.
      • Prognosis: The test will determine prognosis.
      • Natural history or recurrence risk: The test will provide or refine estimates of natural history, recurrence risk, or the predicted course of the genetic condition.
    • CLIA laboratory: Testing is performed in a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory.CLIA-approved laboratory

    Oncology Algorithmic Testing

    Oncology algorithmic testing may be medically necessary when ALL of the following are met:

    Oncology algorithmic criteria

    • Suspected or confirmed neoplasm or malignancy: The member/enrollee has a suspected or confirmed neoplasm and/or malignancy.
    • Clinical validity: The test has clinical validity.
    • ONE clinical-utility pathway

      • Therapeutic response or harm: The test will determine whether a therapeutic intervention is effective or ineffective, or whether an intervention may be harmful.
      • Clinical management: The test will directly impact clinical management.
      • Prognosis: The test will determine prognosis.
      • Natural history or recurrence risk: The test will provide or refine estimates of natural history, recurrence risk, or the predicted course of the genetic condition.

    Other Genetic or Molecular Tests

    Other genetic or molecular tests may be medically necessary when ALL of the following are met:

    Other genetic or molecular test criteria

    • Relevant clinical features: The member/enrollee displays relevant clinical features consistent with the intended use of the test.
    • Clinical validity: The test has clinical validity.
    • ONE clinical-utility pathway

      • Therapeutic response or harm: The test will determine whether a therapeutic intervention is effective or ineffective, or whether an intervention may be harmful.
      • Clinical management: The test will directly impact clinical management.
      • Prognosis: The test will determine prognosis.
      • Natural history or predicted course: The test will provide or refine estimates of natural history or the predicted course of the disease or genetic condition.
    • CLIA laboratory: Testing is performed in a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory.CLIA-approved laboratory

    Complex or Poorly Understood Clinical Disorders

    A definitive genetic diagnosis may have clinical utility for patients with complex or poorly understood clinical disorders, including autism spectrum disorders and intellectual disability.

    Clinical-utility situation

    • Complex or poorly understood disorder: The patient has a complex or poorly understood clinical disorder, such as an autism spectrum disorder or intellectual disability.
    • Definitive diagnosis: A definitive genetic diagnosis may inform causality, prognosis, or treatment.

    Rare Disorders

    A definitive genetic diagnosis may have clinical utility for patients with rare disorders, including disorders evaluated by chromosome analysis or microarray.

    Clinical-utility situation

    • Rare disorder: The patient has a rare disorder, including a disorder evaluated by chromosome analysis, such as karyotype, or by microarray.
    • Definitive diagnosis: A definitive diagnosis may provide clinical utility even when specific prognosis or medical-management guidance is not yet available.

    Newborn Screening

    Newborn screening may have clinical utility for conditions recommended by the Secretary's Discretionary Advisory Committee on Heritable Disorders of Newborns and Children.

    Newborn-screening clinical-utility situation

    • Recommended condition: The newborn screening evaluates a condition recommended by the Secretary's Discretionary Advisory Committee on Heritable Disorders of Newborns and Children.

    Medically Actionable Secondary Findings

    Genomic testing may have clinical utility when it identifies medically actionable secondary findings associated with treatments that can improve or affect outcomes.

    Medically actionable secondary finding

    • Genomic finding: A medically actionable secondary finding is discovered during genomic testing.
    • Actionable treatment: The finding is associated with a treatment that can improve or affect the patient's outcome.

    Occult Primary Cancer

    Somatic or tumor molecular testing may be clinically useful for patients with an occult primary cancer who are candidates for anticancer therapy.

    Occult-primary cancer testing situation

    • Occult primary cancer: The patient has an occult primary cancer.
    • Candidate for anticancer therapy: The patient is a candidate for anticancer therapy.
    • Therapeutic molecular information: Somatic or tumor molecular testing is used to identify uncommon genetic changes within the tumor that may inform anticancer therapy.
    Documentation Required

    Document prenatal recurrence risk

    For prenatal testing related to recurrence risk or a prior affected child, document the relevant parental, pregnancy, family, and prior-child diagnostic information. Molecular confirmation in the affected child may be necessary to make recurrence testing informative and to assess future-pregnancy risk accurately.

    Denial Risk

    Avoid nonqualifying familial-variant testing

    Do not submit targeted testing for a known familial variant of uncertain significance as medically necessary; the policy considers it investigational. Known familial variant analysis is also investigational for indications outside the stated medically necessary criteria.

    Denial Risk

    Confirm carrier-screening eligibility

    Targeted carrier screening is investigational when the indication is not pregnancy or pregnancy planning for a childhood-onset recessive disorder with a qualifying risk factor. Qualifying risk factors include a relevant familial variant, a carrier reproductive partner, a population carrier rate of 1% or higher, or an affected first- or second-degree relative.

    Denial Risk

    Support medical necessity for panel testing

    Single-gene or multigene panel analysis is investigational unless the required clinical features, unresolved diagnosis after appropriate evaluation and standard testing, clinical validity, clinical utility, exclusion of a more appropriate targeted familial-variant test, exclusion of non-genetic causes, and established gene-disease association are demonstrated.

    Denial Risk

    Do not order nonqualifying prenatal diagnosis

    Prenatal single-gene diagnosis is investigational for variants of unknown significance and for other indications outside the stated criteria. Prenatal diagnosis for adult-onset single-gene disorders is not medically necessary.

    Denial Risk

    Meet support requirements for other molecular tests

    Tumor biomarker analysis, oncology algorithmic testing, and other genetic or molecular tests are investigational when their respective clinical-condition, clinical-validity, clinical-utility, or laboratory requirements are not met. For tumor biomarker analysis, the patient must have a confirmed neoplasm or malignancy; oncology algorithmic testing requires a suspected or confirmed neoplasm or malignancy.

    Note

    Offer genetics-experienced counseling

    Genetic counseling is recommended for patients at risk for inherited disorders who are considering genetic testing and should be provided by someone with experience and expertise in genetic medicine and testing methods. Counseling should address potential results, sensitivity, specificity, risks, limitations, benefits, predictive values, residual risk where applicable, follow-up diagnostic testing, and the patient’s option to decline testing.

    Documentation Required

    Perform the required multigene-panel review

    Before ordering a multigene panel, evaluate analytic validity, clinical validity, and clinical utility, and review the patient’s clinical and family history. Also assess panel gene content, sequencing and informatics limitations, and variant interpretation and reporting practices.

    Germline pathogenic or likely pathogenic variant
    DefinitionA mutation occurring in an egg or sperm cell that is inherited and passed down through blood relatives.
    LocationThe alteration occurs in germ cells and becomes incorporated into the DNA of every cell in the body.
    Disease associationMost germline mutations do not result in disease; coverage criteria refer specifically to pathogenic or likely pathogenic variants.
    Somatic variant
    DefinitionA genetic alteration occurring at the level of an individual cell or group of cells.
    ExtentThe alteration is limited to that cell or group of cells.
    InheritanceA somatic variant cannot be passed down to offspring.
    Multifactorial condition
    DefinitionA complex condition caused by a combination of inherited and environmental factors.
    Genetic contributionThe condition may result from the combined effects of multiple genes.
    Environmental contributionInteractions between genes and the environment may contribute to the condition.
    Close relatives
    DefinitionFirst-, second-, and third-degree blood relatives on the same side of the family.
    First-degree relativesParents, siblings, and children.
    Second-degree relativesGrandparents, aunts, uncles, nieces, nephews, grandchildren, and half siblings.
    Third-degree relativesGreat grandparents, great aunts, great uncles, great grandchildren, and first cousins.
    Clinical validity
    DefinitionThe accuracy with which a test identifies a particular clinical condition.
    Diagnostic measuresClinical validity includes sensitivity, specificity, positive predictive value, and negative predictive value.
    PurposeThese measures assess how accurately the test identifies the condition.
    Clinical utility
    DefinitionThe risks and benefits resulting from genetic test use.
    Outcome considerationClinical utility considers whether the test and subsequent interventions improve outcomes among people with a positive result.
    Risk considerationClinical utility also considers what risks occur as a result of testing.
    Algorithmic test
    DefinitionA test that combines biomarkers and clinical data into an algorithm.
    OutputsThe algorithm may generate a disease-risk assessment, prognostic result, or clinical recommendation for treatment.
    Data inputsThe test uses biomarker results together with clinical data.
    Recessive condition
    DefinitionA condition in which both copies of a gene have a mutation, or an individual with one X chromosome is hemizygous for a mutation.
    Autosomal inheritanceMutation of both gene copies results in an autosomal recessive condition.
    X-linked inheritanceHemizygosity for a mutation in an individual with one X chromosome results in an X-linked recessive condition.
    Clinical validity
    DefinitionThe accuracy with which a test identifies a person with the clinical condition in question.
    Core measuresClinical validity is assessed using sensitivity, specificity, positive predictive value, and negative predictive value.
    InterpretationThese measures help determine how reliably a test can confirm or refute a suspected diagnosis.
    Clinical utility
    DefinitionThe risks and benefits resulting from genetic test use.
    Health outcomesClinical utility considers whether testing and subsequent interventions improve health outcomes.
    Testing risksClinical utility also considers the risks resulting from testing.
    ACCE Model
    DefinitionA clinical framework developed by the CDC Office of Public Health Genomics to evaluate a genetic test.
    Evaluation domainsThe model addresses analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications.
    Targeted questionsThe ACCE process uses 44 targeted questions addressing the disorder, testing, clinical scenarios, and the evaluation domains.
    Multianalyte assays with algorithmic analyses (MAAAs)
    DefinitionTests that combine two or more biochemical or molecular markers with patient demographics and clinical information in an algorithm.
    Algorithm outputsThe algorithm generates diagnostic, prognostic, or predictive information for a disease.
    Clinical purposeCombining multiple analytes may improve or refine disease detection through individualized risk assessment.
    Clinical validity
    DefinitionThe accuracy with which a diagnostic test identifies a person with the clinical condition in question.
    Predictive valuesPositive and negative predictive values help determine how reliably the test confirms or refutes a suspected diagnosis.
    Additional measuresClinical validity is also assessed using sensitivity and specificity.
    Clinical utility
    DefinitionThe risks and benefits resulting from genetic test use.
    Intervention effectsClinical utility considers whether the test and subsequent interventions improve health outcomes.
    Management impactTesting is clinically useful when its results can affect clinical care or subsequent interventions while accounting for testing risks.
    Multianalyte assay with algorithmic analysis
    DefinitionA test that combines results from two or more biochemical or molecular markers with patient demographics and clinical information in an algorithm.
    Information generatedThe algorithm generates diagnostic, prognostic, or predictive information.
    Risk assessmentCombining multiple analytes with clinical information can support a personalized assessment of disease risk.